| 04/30/2026 12:03 PM | Regeneron Pharmaceuticals (872589) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/29/2026 5:54 AM | Regeneron Pharmaceuticals (872589) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/29/2026 5:50 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/24/2026 3:02 PM | Regeneron Pharmaceuticals (872589) Filer | Form DEF 14A | |
| 04/24/2026 3:04 PM | Regeneron Pharmaceuticals (872589) Filer | Form DEFA14A | |
| 04/08/2026 6:05 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/03/2026 3:01 PM | Regeneron Pharmaceuticals (872589) Issuer RYAN ARTHUR F (1187443) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/27/2026 10:37 AM | Regeneron Pharmaceuticals (872589) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/03/2026 3:01 PM | Regeneron Pharmaceuticals (872589) Issuer RYAN ARTHUR F (1187443) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 3:55 PM | Regeneron Pharmaceuticals (872589) Issuer Zoghbi Huda Y (1681643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/04/2026 8:08 AM | Regeneron Pharmaceuticals (872589) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 01/30/2026 5:51 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/12/2026 5:48 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 11:03 AM | Bassler Bonnie L (1683607) Reporting Regeneron Pharmaceuticals (872589) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:16 PM | Guarini Kathryn (1992352) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:16 PM | Regeneron Pharmaceuticals (872589) Issuer SING GEORGE L (1225471) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:18 PM | Regeneron Pharmaceuticals (872589) Issuer Thompson Craig B. (1423419) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:03 PM | POON CHRISTINE A (1189014) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:08 PM | Bassler Bonnie L (1683607) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 4:53 PM | Regeneron Pharmaceuticals (872589) Issuer SCHLEIFER LEONARD S (1218629) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 4:54 PM | Regeneron Pharmaceuticals (872589) Issuer YANCOPOULOS GEORGE (1226690) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/31/2025 4:05 PM | Regeneron Pharmaceuticals (872589) Issuer SING GEORGE L (1225471) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 3:27 PM | Regeneron Pharmaceuticals (872589) Issuer YANCOPOULOS GEORGE (1226690) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 3:30 PM | McCourt Marion (1663758) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 3:32 PM | MURPHY ANDREW J (1796226) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 3:34 PM | Regeneron Pharmaceuticals (872589) Issuer Van Plew Daniel P (1411984) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 3:23 PM | Regeneron Pharmaceuticals (872589) Issuer SCHLEIFER LEONARD S (1218629) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 4:38 PM | Pitofsky Jason (2009236) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 3:31 PM | Regeneron Pharmaceuticals (872589) Issuer Van Plew Daniel P (1411984) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 3:08 PM | Fenimore Christopher R. (1697422) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 3:09 PM | LAROSA JOSEPH J (1238303) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 3:10 PM | McCourt Marion (1663758) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 3:07 PM | LAROSA JOSEPH J (1238303) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/20/2025 1:31 PM | Bassler Bonnie L (1683607) Reporting Regeneron Pharmaceuticals (872589) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/07/2025 4:06 PM | Pitofsky Jason (2009236) Reporting Regeneron Pharmaceuticals (872589) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/07/2025 3:55 PM | Regeneron Pharmaceuticals (872589) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 10/31/2025 3:09 PM | POON CHRISTINE A (1189014) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/31/2025 3:06 PM | MURPHY ANDREW J (1796226) Reporting Regeneron Pharmaceuticals (872589) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/29/2025 3:36 PM | POON CHRISTINE A (1189014) Reporting Regeneron Pharmaceuticals (872589) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/28/2025 5:50 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/28/2025 5:56 AM | Regeneron Pharmaceuticals (872589) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
|
| 10/06/2025 6:00 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/06/2025 11:11 AM | FMR LLC (315066) Filed by Regeneron Pharmaceuticals (872589) Subject | Form SCHEDULE 13G/A | |
| 08/01/2025 5:56 AM | Regeneron Pharmaceuticals (872589) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/01/2025 5:49 AM | Regeneron Pharmaceuticals (872589) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2025 10:11 AM | JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by Regeneron Pharmaceuticals (872589) Subject | Form SCHEDULE 13G/A | |